Clinical effects and quality of life of flupentixol-melitracen compared with paroxetine hydrochloride in treatment of breast cancer patients with anxiety and depression after chemotherapy
- VernacularTitle:氟哌噻吨美利曲辛和盐酸帕罗西汀对乳腺癌患者化疗后焦虑抑郁情绪和生活质量影响的比较研究
- Author:
Xuliang ZHANG
;
Kaina ZHOU
- Publication Type:Journal Article
- Keywords:
flupentixol-melitracen;
paroxetine hydrochloride;
breast cancer;
anxiety;
depression;
quality of life
- From:
Chinese Journal of Biochemical Pharmaceutics
2015;(9):67-69,72
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical effects and the quality of life of flupentixol-melitracen or paroxetine hydrochloride in treatment of the breast cancer patients with anxiety and depression after chemotherapy.Methods 135 breast cancer patients with anxiety and depression after chemotherapy were selected from November 2012 to January 2014 in the hospital.They were randomly divided into the treatment group ( n=68 ) and control group ( n =67 ).The control group were treated by paroxetine hydrochloride treatment, and the treatment group were treated by flupentixol-melitracen.The anxiety, depression and its impact on quality of life of patients were observed between two groups.Results After treatment, the HAMD score and HAMA score decreased significantly in two groups (P<0.05), HAMD score and HAMA score in treatment group after treatment significantly decreased compared with control group (P<0.05).After treatment, the WHOQOL-BREF score of mental health status scale of subjective feeling, the physiological domain, domain score levels in treatment group significantly increased (P<0.05), however, the quality of life of subjective feeling, social relationship and environment domains showed no significant difference.Compared with pre-treatment, only the health status of subjective feeling levels in control group post-treatment significantly increased (P<0.05).The mental health status scale of subjective feeling, the physiological domain, domain score levels in treatment group significantly decreased compared with control group ( P<0.05 ).The adverse reactions of treatment group were 5 cases (7.35%), which was significantly lower than 24 cases (35.82%) of control group(χ2 =16.22,P <0.05).Conclusion Flupentixol-melitracen combined with paroxetine hydrochloride has an obvious clinical effect in treatment of anxiety and depression in patients with breast cancer after chemotherapy.It could effectively control their anxiety and depression, and improve the quality of life of patients.It is worthy of clinical popularization and application.
